The Delhi High Court has granted permission to Zydus to market a more affordable biosimilar version of the cancer medication Nivolumab, citing public interest.
The Delhi High Court has given a significant ruling in favor of Zydus, a pharmaceutical company, allowing it to sell a biosimilar version of the cancer drug Nivolumab at a lower price. Nivolumab, marketed under the brand name Opdivo by Bristol Myers Squibb, is a monoclonal antibody used to treat various types of cancer, including melanoma, lung cancer, and kidney cancer. The court’s decision is expected to make the life-saving drug more accessible to patients in India.
Zydus had launched its biosimilar version of Nivolumab, called Itolizumab, in India, which is priced significantly lower than the original drug. However, Bristol Myers Squibb had approached the court, seeking an injunction to stop Zydus from selling the biosimilar, claiming that it infringed on their patent. The court, after hearing the arguments, ruled in favor of Zydus, stating that the company can continue to sell its biosimilar version of Nivolumab in the public interest.
The court’s decision is based on the fact that Nivolumab is a life-saving drug, and its high price makes it inaccessible to many patients in India. The court observed that the price of the original drug is exorbitant, and the biosimilar version launched by Zydus is priced at a significantly lower rate, making it more affordable for patients. The court also noted that Zydus has invested significant resources in developing the biosimilar and has obtained all necessary regulatory approvals.
The ruling is a significant win for patients in India, who will now have access to a more affordable version of the life-saving drug. The decision is also expected to have a positive impact on the Indian pharmaceutical industry, as it will encourage other companies to develop and launch biosimilars of expensive drugs, making them more accessible to patients.
The court’s decision is in line with the government’s efforts to make healthcare more affordable and accessible to all. The government has been promoting the use of biosimilars and generic drugs to reduce the cost of healthcare and make life-saving drugs more accessible to patients. The ruling is also expected to set a precedent for future cases, where pharmaceutical companies may approach the court to stop the sale of biosimilars, citing patent infringement. Overall, the court’s decision is a significant step towards making healthcare more affordable and accessible to all in India.
Piramal Pharma Enhances Its Global Sustainability Rating in Recent Corporate Assessment.
Piramal Pharma, a leading global pharmaceutical company, has achieved a significant improvement in its score on the Global Corporate Sustainability Assessment (CSA) conducted by S&P Global. The CSA is a widely recognized benchmark for assessing a company’s sustainability performance, evaluating factors such as environmental, social, and governance (ESG) practices.
In the latest assessment, Piramal Pharma’s score has increased by 13 points, reaching a total of 73 out of 100. This improvement reflects the company’s ongoing efforts to integrate sustainability into its business strategy and operations. The CSA assessment is based on a comprehensive evaluation of a company’s sustainability practices, including climate change, human rights, labor practices, and corporate governance.
The significant improvement in Piramal Pharma’s score can be attributed to its focused efforts on reducing its environmental footprint, enhancing its governance practices, and promoting social responsibility. Some of the key initiatives that contributed to this improvement include:
- Renewable energy: Piramal Pharma has increased its use of renewable energy sources, such as solar and wind power, to reduce its dependence on fossil fuels and lower its carbon emissions.
- Water conservation: The company has implemented water-saving measures and efficient wastewater management systems to minimize its water footprint.
- Waste reduction: Piramal Pharma has implemented a waste reduction program, which includes recycling and composting, to minimize waste disposal and reduce its environmental impact.
- Corporate governance: The company has strengthened its corporate governance practices, including board composition, executive compensation, and auditing practices.
- Social responsibility: Piramal Pharma has continued to invest in social responsibility initiatives, such as education, healthcare, and community development programs, to promote positive social impact.
The improved score on the Global Corporate Sustainability Assessment reflects Piramal Pharma’s commitment to sustainability and its efforts to create long-term value for its stakeholders. The company’s focus on sustainability is aligned with its mission to improve the quality of life for patients and communities worldwide. By integrating sustainability into its business strategy, Piramal Pharma aims to minimize its environmental footprint, promote social responsibility, and ensure long-term success.
Overall, Piramal Pharma’s achievement on the Global Corporate Sustainability Assessment demonstrates its dedication to sustainability and its commitment to creating a positive impact on the environment, society, and the economy. The company’s improved score serves as a testament to its efforts to balance business growth with social and environmental responsibility, making it a leader in the pharmaceutical industry.
Aurobindo Pharma Acquires Khandelwal Labs’ Non-Cancer Portfolio for ₹325 Crore.
Aurobindo Pharma, a leading Indian pharmaceutical company, has acquired the non-oncology business of Khandelwal Laboratories for ₹325 crore. The acquisition is a strategic move by Aurobindo Pharma to expand its product portfolio and strengthen its position in the domestic market.
Khandelwal Laboratories is a Mumbai-based pharmaceutical company that operates in the areas of oncology and non-oncology. The company has a strong product portfolio in the non-oncology segment, with a focus on therapeutic areas such as neurology, cardiology, and gastroenterology. The non-oncology business of Khandelwal Laboratories includes a range of products, including tablets, capsules, and injectables.
The acquisition of Khandelwal Laboratories’ non-oncology business will add over 50 products to Aurobindo Pharma’s portfolio, including some well-established brands. The products will be marketed and distributed by Aurobindo Pharma’s existing sales team, which has a strong presence in the domestic market. The acquisition is expected to be completed in the next few months, subject to regulatory approvals.
Aurobindo Pharma has stated that the acquisition is in line with its strategy to expand its product portfolio and increase its presence in the domestic market. The company has been looking to strengthen its position in the Indian market, where it faces intense competition from other pharmaceutical companies. The acquisition of Khandelwal Laboratories’ non-oncology business is expected to help Aurobindo Pharma achieve this objective.
The acquisition is also expected to be beneficial for Khandelwal Laboratories, as it will allow the company to focus on its oncology business. Khandelwal Laboratories has a strong presence in the oncology segment, and the company is expected to use the proceeds from the sale to invest in its oncology business.
The deal is valued at ₹325 crore, which is a significant amount for a pharmaceutical company of Khandelwal Laboratories’ size. The acquisition price includes the cost of acquiring the non-oncology business, including the products, manufacturing facilities, and marketing rights. Aurobindo Pharma has stated that the acquisition will be funded through a combination of internal accruals and debt.
Overall, the acquisition of Khandelwal Laboratories’ non-oncology business by Aurobindo Pharma is a significant development in the Indian pharmaceutical industry. The deal is expected to strengthen Aurobindo Pharma’s position in the domestic market and provide the company with a strong portfolio of products in the non-oncology segment.
Lupin partners with Gan & Lee to bring fortnightly GLP-1 treatment to India through exclusive licensing deal.
Lupin Limited, a global pharmaceutical company, has entered into an exclusive agreement with Gan&Lee Pharmaceuticals of China to commercialize Bofanglutide, a novel GLP-1 receptor agonist, in India. Bofanglutide is a fortnightly treatment for type 2 diabetes and weight management in overweight and obese adults, offering a reduced injection frequency compared to existing weekly GLP-1 therapies. Clinical data shows that the drug delivers comparable or better weight loss and glycaemic control outcomes, with a safety and tolerability profile consistent with the GLP-1 class.
The agreement strengthens Lupin’s metabolic health portfolio and marks its entry into the obesity treatment segment. India faces a significant burden of metabolic diseases, with an estimated 90 million adults living with diabetes and 50 million classified as obese. The convenience of a fortnightly dosing regimen may improve treatment adherence for patients requiring long-term therapy. Lupin’s Managing Director, Nilesh Gupta, commented that the agreement reflects the company’s commitment to expanding access to innovative therapies for chronic metabolic conditions.
The partnership also aligns with Gan&Lee Pharmaceuticals’ strategy to expand globally and bring its innovations to new markets. The company is a leading insulin manufacturer in China and has received regulatory approvals in multiple international markets. Lupin Limited, headquartered in Mumbai, operates in over 100 markets worldwide, with a strong presence in India and the United States. The company manufactures a range of products, including branded and generic formulations, complex generics, biotechnology products, and APIs, across 15 manufacturing sites and seven research centers globally.
The agreement is expected to benefit patients in India, where there is a growing need for effective treatments for metabolic diseases. With its strong presence in the Indian market, Lupin is well-positioned to commercialize Bofanglutide and make it accessible to patients who need it. The partnership between Lupin and Gan&Lee Pharmaceuticals is a significant development in the field of metabolic health and is expected to have a positive impact on the lives of millions of people in India and beyond.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.